Although the advantages of CGM use in T1D are well archived, its effectiveness over the spectrum of T2D patients in real-world settings has not been assessed. Satish K. Garg & team aimed to evaluate the impacts of CGM use in a large T2D adult population over the therapy spectrum, contemplating non-insulin therapies (NIT), basal insulin (BIT), and prandial insulin (PIT) with/without non-insulin medicines. The findings were presented at the 84^th Scientific Sessions of the ADA Congress 2024, held in Orlando from 21^st – 24^th June 2024.

A large claims database was used for this retrospective,12-month examination that incorporated >7.1 million patients with T2D in the electronic medical records. The 2 observation periods were: pre-index period — 360 days earlier to patients’ first CGM claim; and post-index period — 360 days following to the first CGM claim. The index date (baseline) was the date of the first CGM claim during December 27, 2019, and January 5, 2022. The primary outcome was change in HbA1c closest to 12 months following CGM acquisition.

16,410 adults with T2D (NIT, n=4,659; (BIT, n=6,182, and PIT, n=5,569) with mean baseline HbA1c 8.8% and mean age 59 years were incorporated in the analysis. At 12 months, all three subgroups exhibited substantial mean change in HbA1c as compared to HbA1c levels in the pre-index period. (Figure)

The authors concluded that CGM use was correlated with substantial enhancements in glucose control in both non-insulin and insulin-managed patients with T2D in this 12-month, real-world study.